Treatment outcomes of MRI-guided adaptive brachytherapy in patients with locally advanced cervical cancer: institutional experiences

Purpose Image-guided adaptive brachytherapy (IGABT) is currently state of the art in the comprehensive treatment of patients with cervical cancer. Here, we report mature clinical data regarding IGABT of cervical cancer in a large patient sample, examining clinical outcomes, manifestations of late to...

Full description

Saved in:
Bibliographic Details
Published inStrahlentherapie und Onkologie Vol. 198; no. 9; pp. 783 - 791
Main Authors Vojtíšek, Radovan, Hošek, Petr, Sukovská, Emília, Kovářová, Petra, Baxa, Jan, Ferda, Jiří, Fínek, Jindřich
Format Journal Article
LanguageEnglish
Published Berlin/Heidelberg Springer Berlin Heidelberg 01.09.2022
Springer Nature B.V
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Purpose Image-guided adaptive brachytherapy (IGABT) is currently state of the art in the comprehensive treatment of patients with cervical cancer. Here, we report mature clinical data regarding IGABT of cervical cancer in a large patient sample, examining clinical outcomes, manifestations of late toxicities, and dosimetric findings. Methods Between May 2012 and October 2020, we performed a total of 544 uterovaginal IGABT applications in 131 consecutive patients with biopsy-proven cervical carcinoma not suitable for surgery. The median duration of follow-up was 43 months. Results The estimated 3‑, 4‑, and 5‑year LC rates were 88.3% (95% confidence interval [CI] 81.1–95.5), 86.9% (95% CI 78.5–95.3), and 85.5% (95% CI 76–95%), respectively. The 3‑, 4‑, and 5‑year OS estimates were 72.66% (95% CI 63.64–81.69%), 68.9% (95% CI 59.15–78.66%), and 63.96% (95% CI 52.94–74.97%), respectively. Patients who received ≥ 5 cycles of chemotherapy had statistically significantly better 3‑year recurrence-free survival (RFS) compared to patients who completed <5 cycles (79.07% [95% CI 60.81–97.34] vs. 58.10% [95% CI 47.22–68.98]; p  = 0.0185). We recorded manifestations of genitourinary and gastrointestinal toxicity grade ≥3 in 6.9% and 5.3%, respectively. Conclusion Our mature long-term data on the treatment patients with locally advanced cervical cancer show that excellent treatment outcomes can be achieved with MRI-based IGABT, as well as acceptable late morbidity.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0179-7158
1439-099X
DOI:10.1007/s00066-021-01887-x